Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
21.46
-0.34 (-1.56%)
At close: Mar 5, 2026, 4:00 PM EST
21.27
-0.19 (-0.89%)
Pre-market: Mar 6, 2026, 9:02 AM EST
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Ultragenyx Pharmaceutical stock have an average target of 66.32, with a low estimate of 25 and a high estimate of 117. The average target predicts an increase of 209.04% from the current stock price of 21.46.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock from 19 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 8 | 8 | 7 |
| Buy | 8 | 8 | 11 | 11 | 11 | 11 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 19 | 20 | 20 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $128 → $79 | Strong Buy | Maintains | $128 → $79 | +268.13% | Feb 18, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $37 → $34 | Buy | Maintains | $37 → $34 | +58.43% | Feb 18, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $39 → $37 | Buy | Maintains | $39 → $37 | +72.41% | Feb 17, 2026 |
| Wedbush | Wedbush | Hold Reiterates $25 | Hold | Reiterates | $25 | +16.50% | Feb 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $60 → $50 | Strong Buy | Maintains | $60 → $50 | +132.99% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
763.16M
from 673.00M
Increased by 13.40%
Revenue Next Year
1.09B
from 763.16M
Increased by 42.83%
EPS This Year
-4.44
from -5.83
EPS Next Year
-0.77
from -4.44
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 863.1M | 1.7B | |||
| Avg | 763.2M | 1.1B | |||
| Low | 597.5M | 858.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.2% | 125.2% | |||
| Avg | 13.4% | 42.8% | |||
| Low | -11.2% | 12.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.10 | 1.92 | |||
| Avg | -4.44 | -0.77 | |||
| Low | -5.50 | -2.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.